Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration

Canadian Journal of Ophthalmology

Volumn 50, Issue 5, 2015, Pages 373-377

  Major, James C ^a   Wykoff, Charles C ^a   Croft, Daniel E ^b   Wang, Rui ^b   Mariani, Angeline F ^b   Lehmann, Anna E ^b   Brown, David M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b RETINA CONSULTANTS OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETINA DETACHMENT; TREATMENT DURATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84944173680     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2014.12.012     Document Type: Article

References (19)

1. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N Engl J Med 358 2008 2606 2617
2. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
3. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular macular degeneration N Engl J Med 355 2006 1432 1444
4. D.F. Martin, M.G. Maguire, G.S. Ying, and et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
5. D.F. Martin, M.G. Maguire, S.L. Fine, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
6. J.S. Heier, D.M. Brown, V. Chong, and et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
7. M.W. Stewart, P.J. Rosenfeld, F.M. Penha, and et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) Retina 32 2012 434 457
8. Q.D. Nguyen, S.M. Shah, D.J. Browning, and et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration Ophthalmology 116 2009 2141 2148 e2141
9. F. Coscas, C. Gabriel, E. Souied, and et al. Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 144 2007 592 599
10. P. Kalouda, A. Anastasakis, C. Tsika, and K.M. Tsilimbaris The effect of intravitreal anti-VEGF on the pigment epithelial detachment in eyes with the exudative type of age-related macular degeneration Semin Ophthalmol 30 2015 6 10
11. M. Ritter, M. Bolz, S. Sacu, and et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment Eye 24 2010 962 968
12. K.H. Patel, C.C. Chow, R. Rathod, and et al. Rapid response of retinal epithelial detachments to intravitreal alibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab Eye (Lond) 27 2013 663 667
13. G.A. Lalwani, P.J. Rosenfeld, and A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study Am J Ophthalmol 148 2009 43 58
14. W.R. Freeman, I. Kozak, R.M. Yuson, and et al. Prognostic implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization Retina 31 2011 1812 1818
15. E. Chen, R.S. Kaiser, and J. Vander Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration Retina 27 2007 445 450
16. K. Pepple, and P. Mruthyunjaya Retinal pigment epithelial detachments in age-related macular degeneration: classification and therapeutic options Semin Ophthalmol 26 2011 198 208
17. E.T. Cunningham, L. Feiner, C. Chung, L. Tuomi, and J.S. Ehrlich Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration Ophthalmology 118 2011 2447 2452
18. C.K. Chan, P. Abraham, C.H. Meyer, and et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections Retina 30 2010 203 211
19. A. Nagiel, K.B. Freund, R.F. Spaide, and et al. Mechanisms of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography Am J Ophthalmol 156 2013 981 988 e2